Bookmark

Add to MyYahoo RSS

Cubist Pharmaceuticals News

News on Cubist Pharmaceuticals (Ticker: CBST) continually updated from thousands of sources around the net.

Tuesday Apr 15 | BioSpace

Cubist Pharmaceuticals, Inc. To Announce First Quarter 2014 Financial ...

Cubist Pharmaceuticals, Inc. will issue its first quarter 2014 financial results at 4:00 p.m. ET on Tuesday, April 22, 2014.

Comment?

Related Topix: Cubist Pharmaceuticals, Biotech, Medicine, Healthcare Industry

Wed Apr 09, 2014

Business Journal

Atlas Venture's newest stab at an antibiotics biotech comes out of stealth

Recent federal legislation designed to encourage the development of new antibiotics is partly responsible for the launch of one of Atlas Venture's newest biotechs.

Comment?

Related Topix: Venture Capital, Emerging Technology, Healthcare Law, Law, Biotech, Cubist Pharmaceuticals, Medicine, Healthcare Industry, Tetraphase Pharmaceuticals, Food and Drug Administration

Tue Apr 08, 2014

The Motley Fool

Pfizer Blockbuster Zyvox Under Attack

With several important revenue streams drying up, this one has become more important than ever to the drug company.

Comment?

Related Topix: Zyvox, Linezolid (generic), Medicine, Healthcare Law, Law, Biotech, Healthcare Industry

Fri Apr 04, 2014

The Motley Fool

What's Next for Cubist Pharmaceuticals Inc. and Durata Therapeutics, Inc.?

In two unanimous votes, the FDA panels agreed on the safety and efficacy of Cubist's tedizolid and Durata's dalbavancin.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, MRSA, Health, Zyvox, Linezolid (generic)

Thu Apr 03, 2014

Sys-Con Media

The Zacks Analyst Blog Highlights: Gilead, MannKind, Cubist, Regeneron and Medicines Co

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.

Comment?

Related Topix: Biotech, Medicines Company The, Medicine, Healthcare Industry, Financial Markets, MannKind, Gilead Sciences, Regeneron Pharmaceuticals

Wed Apr 02, 2014

Seeking Alpha

Durata Therapeutics: Gains Ahead

Durata Therapeutics is a biotech company focused on the development of novel antibiotics for acute infectious skin diseases.

Comment?

Related Topix: Biotech, Cubist Pharmaceuticals, Healthcare Industry, Marketing

BioResearch Online

Antibiotic R&D Gains Traction: A Mid-Cap Company Leads The Way

The industry leader in developing antibiotics against "superbugs" and other multidrug-resistant bacteria is not a Big Pharma corporation, but Cubist Pharmaceuticals, headquartered in Lexington, MA.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals, MRSA, Health, Healthcare Law, Law, Food and Drug Administration, Marketing

Tue Apr 01, 2014

P&T Community

FDA Advisors Back Two Antibiotics for ABSSSIs

The FDA's Anti-Infective Drugs Advisory Committee voted unanimously to recommend approval of two antibiotics for the treatment of acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus aureus .

Comment?

Related Topix: Food and Drug Administration, MRSA, Health, Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

AmericanBankingNews.com

Cubist Pharmaceuticals Receives Buy Rating from Aegis

's stock had its "buy" rating reaffirmed by analysts at Aegis in a research report issued to clients and investors on Tuesday, Analyst RN reports.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

Freshnews

Cubist Appoints Robert J. Perez to Board of Directors

Cubist today announced the appointment of Robert J. Perez to its Board of Directors.

Comment?

Related Topix: Cubist Pharmaceuticals, Biotech, Medicine, Healthcare Industry, Corporate Governance, Marketing, Cal State Los Angeles

Mon Mar 31, 2014

BioSpace

Cellceutix Reports 20 Percent Enrollment Completed In Phase 2b Trial...

Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to provide shareholders an update on the status of the Company's clinical trial of its novel antibiotic Brilacidin as a treatment for Acute Bacterial Skin and Skin Structure ... (more)

Comment?

Related Topix: Healthcare Law, Law, Oncology, Medicine, Dermatology, Biotech, Cubist Pharmaceuticals, Healthcare Industry, Food and Drug Administration

Pharmaceutical Processing

FDA Advisory Committee Recommends Approval of Cubist's SIVEXTROa

Cubist Pharmaceuticals has announced today that the FDA Anti-Infective Drugs Advisory Committee voted to recommend approval of Cubist's investigational antibiotic SIVEXTROa .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals, MRSA, Health

Freshnews

FDA Advisory Committee Unanimously Recommends Approval of Cubist's...

Cubist Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration Anti-Infective Drugs Advisory Committee voted to recommend approval of Cubist's investigational antibiotic SIVEXTRO .

Comment?

Related Topix: Food and Drug Administration, Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals, MRSA, Health

Business Journal

FDA panel votes in favor of approval for Cubist's new MRSA drug

An advisory committee to the U.S. Food and Drug Administration voted unanimously in favor of approval for the newest antibiotic by Cubist Pharmaceuticals , according to a spokeswoman for the company.

Comment?

Related Topix: Biotech, Food and Drug Administration, Medicine, Healthcare Industry, Cubist Pharmaceuticals

Reuters

FDA panel says Cubist anti-infective shows efficacy, safety

Cubist Pharmaceuticals Inc's anti-infective tedizolid for acute bacterial skin infections shows substantial evidence of safety and efficacy, an advisory panel to the U.S. Food and Drug Administration concluded on Monday.

Comment?

Related Topix: Food and Drug Administration, Biotech, Medicine, Healthcare Industry

Fri Mar 28, 2014

Business Journal

On Monday, Cubist will seek U.S. approval of a new MRSA drug

For the first time in eight years, executives from Cubist Pharmaceuticals will trek down to Silver Springs, Md., on Monday to take part in the high-stakes hearing required for approval of a new drug in the U.S. Representatives from the Lexington drug company will appear before an advisory board to the U.S. Food and Drug Administration to seek ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals, Food and Drug Administration

Thu Mar 27, 2014

AmericanBankingNews.com

Cantor Fitzgerald Increases Cubist Pharmaceuticals Price Target to $73.00

Cantor Fitzgerald's target price suggests a potential upside of 0.61% from the company's current price.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

Canadian Business Magazine

This new killer antibiotic beats deadly bacteria by targeting their defence system

Antibiotic-resistant bacteria are one of the biggest public health threats facing us today.

Comment?

Related Topix: Infectious Diseases, Medicine, Biotech, Healthcare Industry, Cubist Pharmaceuticals

Thu Mar 20, 2014

Business Journal

A year after IPO, 'the world has changed' for Tetraphase

A year after going public, the head of Watertown-based Tetraphase says the investment world has become far more receptive to antibiotic biotech firms like his.

Comment?

Related Topix: Biotech, Cubist Pharmaceuticals, Medicine, Healthcare Industry

The Motley Fool

Better Buy: Cubist Pharmaceuticals, Inc. vs. Durata Therapeutics, Inc.

Regulatory decisions are generally chaotic events for biotech companies, especially when they involve a lead clinical candidate.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Healthcare Law, Law, Food and Drug Administration, Centers for Disease Control and Prevention, MRSA, Health

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••
•••